BriaCell Therapeutics Corp.
BCT.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.79% | 11.90% | -1.31% | -32.06% | 2.61% |
| Total Depreciation and Amortization | 23.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -86.91% | -36.90% | 150.30% | -3,561.31% | 102.61% |
| Change in Net Operating Assets | 109.92% | -505.36% | -44.00% | 137.76% | -223.69% |
| Cash from Operations | 11.88% | -3.41% | 5.26% | -13.54% | -20.99% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -318.00% | 9,810.00% | 98.99% | -6,939.05% | -40.00% |
| Cash from Investing | -319.75% | 9,810.00% | 98.99% | -6,939.05% | -40.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -7.87% | 182.07% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -- | -7.87% | 182.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.68% | 449.49% | -295.64% | -126.41% | 1,056.41% |